Amide Patents (Class 562/455)
-
Patent number: 6972300Abstract: Modified amino acid compounds useful in the delivery of active agents are provided. The active agents can be peptides, such as rhGH. Methods of administration, such as oral, subcutaneous, sublingual, and intranasal administration, are provided, and methods of preparation of the modified amino acid compound are provided.Type: GrantFiled: July 18, 2003Date of Patent: December 6, 2005Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Koc-Kan Ho, Donald J. Sarubbi, Sam J. Milstein
-
Patent number: 6888022Abstract: Disclosed are compounds which inhibit ?-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits ?-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.Type: GrantFiled: February 20, 2001Date of Patent: May 3, 2005Assignees: Athena Neurosciences, Inc., Eli Lilly & CompanyInventors: James E. Audia, Thomas C. Britton, James J. Droste, Beverly K. Folmer, George W. Huffman, Varghese John, Lee H. Latimer, Thomas E. Mabry, Jeffrey S. Nissen, Warren J. Porter, Jon K. Reel, Eugene D. Thorsett, Jay S. Tung, Jing Wu, Clark Norman Eid, William Leonard Scott
-
Patent number: 6861391Abstract: Trifluoromethyl-substituted spirocyclic ketoenols of the formula (I) are provided wherein Het represents one of the groups and G, V, W, X, Y, and Z are as defined in the specification. Also provides are processes for the preparation of the compounds. The compounds of formula (I) find use as pesticides.Type: GrantFiled: September 19, 2000Date of Patent: March 1, 2005Assignee: Bayer AktiengesellschaftInventors: Reiner Fischer, Alan Graff, Thomas Bretschneider, Christoph Erdelen, Mark Wilhelm Drewes, Dieter Feucht
-
Patent number: 6849742Abstract: The present invention provides a binaphthol compound represented by formula [1]: and a salt thereof. The binaphthol compound of the present invention is useful for manufacturing antiseptic compounds or chiral catalysts. According to the method of the present invention, binaphthol compounds can be prepared in high yield with low cost.Type: GrantFiled: April 18, 2002Date of Patent: February 1, 2005Assignee: Kabushiki Kaisha Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Masaya Kitayama, Kenji Minami, Hiroyuki Wakamori
-
Patent number: 6846844Abstract: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: August 16, 2001Date of Patent: January 25, 2005Assignee: Emisphere Technologies, Inc.Inventor: Pingwah Tang
-
Patent number: 6838574Abstract: A medicament comprising as an active ingredient a compound or a physiologically acceptable salt thereof represented by general formula (I): wherein R1 represents a dicarba-closo-dodecaboran-yl which may be substituted with a lower alkyl group, a lower alkenyl group, carboxyl group or the like; R2 represents carboxyl group, a lower alkoxycarbonyl group, or hydroxyl group; and X represents a single bond or a linking group such as —CO—Y1— wherein Y1 represents oxygen or —N(R3)— wherein R3 represents hydrogen or a lower alkyl.Type: GrantFiled: January 21, 2000Date of Patent: January 4, 2005Assignee: Institute of Medicinal Molecular Design, Inc.Inventor: Yasuyuki Endo
-
Patent number: 6831102Abstract: New thyroid receptor ligands are provided which have the general formula I: wherein R1 is halogen, trifluoromethyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-6 alkyl, or substituted or unsubstituted C3-7 cycloalkyl; R2 and R3 are each independently hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, or substituted or unsubstituted C3-6 cycloalkyl, wherein at least one of R2 and R3 is other than hydrogen; R4 is a carboxylic acid selected from the group consisting of (CH2)nCOOH, (CH)2COOH, NHCO(CH2)nCOOH, CONH(CH2)nCOOH and NH(CH2)mCOOH; n is an integer from 0 to 4; and m is an integer from 1 to 4. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.Type: GrantFiled: December 6, 2002Date of Patent: December 14, 2004Assignee: Bristol-Myers Squibb CompanyInventor: Jon J. Hangeland
-
Patent number: 6806381Abstract: Provided are processes for the synthesis of aniline derivatives, specifically certain aniline derivatives which have activity as thyroid receptor ligands.Type: GrantFiled: October 17, 2002Date of Patent: October 19, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Ramakrishnan Chidambaram, Joydeep Kant, Raymond E. Weaver, Jurong Yu, Arun Ghosh
-
Patent number: 6762320Abstract: This invention relates to N-acylamino aryl derivatives of the formula where R1, R21, R22, R23, R24, R3, R4, R5 R6, R7, R8, R, and n are as defined herein and where X is —CHRO, —OCHR—, —CH2S—, —SCH2—, —CH2CH2—, —CH═CH— or —C≡C—. The compounds of the invention are selective monoamine oxidase B inhibitors, and they are therefore useful in the treatment of diseases mediated by monoamine oxidase B, for example, for the treatment of Alzheimer's disease or senile dementia.Type: GrantFiled: May 27, 2003Date of Patent: July 13, 2004Assignee: Hoffman-La Roche Inc.Inventors: Synese Jolidon, Rosa Maria Rodriguez Sarmiento, Andrew William Thomas, Rene Wyler
-
Patent number: 6720452Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.Type: GrantFiled: June 10, 2002Date of Patent: April 13, 2004Assignee: AstraZeneca ABInventors: Lilian Alcaraz, Mark Furber, Timothy Luker, Michael Mortimore, Philip Thorne
-
Patent number: 6710205Abstract: An agent comprising the benzoic acid of formula (I) wherein A, B, R6, R7 are carbocyclic ring, heterocyclic ring, etc.; R1 is hydroxy etc.; R2, R3, R4 are alkyl etc.; R5, D, E are alkylene, etc.; G is oxygen etc., as active ingredient. The compound of formula (I) is considered to be useful for the treatment and/or prophylaxis of bone diseases, cancer, systemic granuloma, immunological diseases, allergy, atopy, asthma, gumboil, gingivitis, periodontitis, neurocyte death, Alzheimer's diseases, lungs injury, pulmopathy, acute hepatitis, nephritis, myocardial ischemia, Kawasaki disease, ambustion, ulcerative colitis, Crohn's disease, multiple organ failure, sleeping disorder, platelet aggregation, etc.Type: GrantFiled: August 16, 2002Date of Patent: March 23, 2004Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kousuke Tani, Kaoru Kobayashi, Takayuki Maruyama
-
Patent number: 6699904Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.Type: GrantFiled: February 14, 2002Date of Patent: March 2, 2004Assignee: Pfizer Inc.Inventors: Cheryl M. Hayward, David A. Perry
-
Patent number: 6649656Abstract: The present invention relates to an anthranilic acid derivative expressed by the following formula (1) or the following formula (2), or its pharmacologically permissible salt or solvate.Type: GrantFiled: April 4, 2001Date of Patent: November 18, 2003Assignee: Teijin LimitedInventors: Naoki Tsuchiya, Susumu Takeuchi, Takumi Takeyasu, Naoki Hase, Takao Yamori, Takashi Tsuruo
-
Patent number: 6642411Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided Methods of administration and preparation are provided as well.Type: GrantFiled: April 19, 2001Date of Patent: November 4, 2003Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Doris O'Toole
-
Patent number: 6620963Abstract: Compounds of the formula where the variables have the meaning defined in the specification, which bind specifically or selectively to to RAR&agr; retinoid receptors.Type: GrantFiled: September 19, 2002Date of Patent: September 16, 2003Assignee: Allergan, Inc.Inventors: Tien T. Duong, Richard Beard, Roshantha A. Chandraratna
-
Patent number: 6605642Abstract: The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of reducing sugars in the blood and in the intracellular environment such as occurs with diabetes. The structural and functional integrity of the affected molecules become perturbed by these modifications and can result in severe consequences. The compounds of the present invention can be used to inhibit this process of nonenzymatic glycation and therefore to inhibit some of the ill effects caused by diabetes or by aging. The compounds are also useful for preventing premature aging, spoilage of proteins in food and can prevent discoloration of teeth.Type: GrantFiled: March 8, 2001Date of Patent: August 12, 2003Assignee: City of HopeInventors: Samuel Rahbar, Iraj Lalezari
-
Patent number: 6600069Abstract: Compounds of Formula I, and pharmaceutical compositions containing these compounds, activate the insulin receptor kinase, which leads to an increased sensitivity to insulin and an increase in glucose uptake, and are therefore useful for the treatment of animals, especially humans, with hyperglycemia, especially for the treatment of type 2 diabetes. Processes for preparation of the compounds, and their use in assays, are also disclosed.Type: GrantFiled: September 6, 2001Date of Patent: July 29, 2003Assignee: Telik, Inc.Inventors: Louise Robinson, Prasad V. V. S. V. Manchem, Nicolas Cairns, Steven R. Schow
-
Publication number: 20030087956Abstract: 1 A compound of formula (I) where D is a VLA-4 specificity determinant which does not impart significant IIB/IIIa activity; R41 is a group of the formula (V): U - (CH2)d - V - T wherein U is selected from oxygen, sulphur, a direct bond or —CH2O—, V is selected from nitrogen, oxygen, sulphur, S(O), S(O)2 or a direct bond, d is zero or a number from 1 to 4, and T is selected from a range of variables defined in the application; and other variables are defined in the application, or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof. The compounds are useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor &agr;4&bgr;1. Pharmaceutical compositions and methods of use or treatment are also described and claimed.Type: ApplicationFiled: June 14, 2002Publication date: May 8, 2003Inventors: Craig Johnstone, Michael Stewart Large
-
Publication number: 20030083505Abstract: New benzenedicarboxylic acid derivative compounds; pharmaceutical compositions, diagnostic methods, and diagnostic kits that include those compounds; and methods of using those compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-&bgr; activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, and glaucoma.Type: ApplicationFiled: June 21, 2002Publication date: May 1, 2003Inventors: Paul F. Jackson, Takashi Tsukamoto, Barbara S. Slusher, Eric Wang
-
Publication number: 20030083267Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.Type: ApplicationFiled: August 22, 2001Publication date: May 1, 2003Applicant: Biogen, Inc., a Massachusetts corporationInventors: Steven P. Adams, Ko-Chung Lin, Wen-Cherng Lee, Alfredo C. Castro, Craig N. Zimmerman, Charles E. Hammond, Yu-Sheng Liao
-
Publication number: 20030073862Abstract: The present invention relates to 2-(benzoylamino)benzoic acid derivatives of the formula I 1Type: ApplicationFiled: July 3, 2002Publication date: April 17, 2003Inventors: Anna-Lena Gustavsson, Lena Jendeberg, Patrick Roussel, Martin Slater, Markus Thor
-
Publication number: 20030065007Abstract: Non-peptide acetamide derivatives of Formula I are specific NK1 antagonists, 1Type: ApplicationFiled: October 9, 2002Publication date: April 3, 2003Inventors: Mark Wallace Creswell, Michael Higginbottom, David Christopher Horwell, Russel Andrew Lewthwaite, Martyn Clive Pritchard, Jennifer Raphy
-
Patent number: 6541521Abstract: Benzene butyric acid compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.Type: GrantFiled: July 12, 1999Date of Patent: April 1, 2003Assignee: Warner-Lambert CompanyInventors: Claude Forsey Purchase, Jr., Bruce David Roth, Andrew David White
-
Patent number: 6534513Abstract: Phenylalkanoic acid derivatives of formula (1) are described: wherein Ar1 is an aromatic or heteroaromatic group; L1 is a covalent bond or a linker atom or group; A is an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; R is a carboxylic acid (—CO2H) or a derivative thereof; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of alpha 4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.Type: GrantFiled: September 29, 1999Date of Patent: March 18, 2003Assignee: Celltech R&D LimitedInventors: John Robert Porter, Graham John Warrellow, Sarah Catherine Archibald, John Clifford Head
-
Patent number: 6528655Abstract: A compound of formula I′ and pharmaceutically acceptable derivatives thereof including, for example, where applicable or appropriate pharmaceutically acceptable salts thereof. Ar and Ar′ are aromatic or aryl type groups. The compounds have HIV integrase inhibitory properties. Ar, Ar′ and W may be as defined in the specification.Type: GrantFiled: September 26, 2001Date of Patent: March 4, 2003Assignee: Pharmacor, Inc.Inventors: Blaise Magloire N'Zemba, Gilles Sauvé, Guy Sévigny, Jocelyn Yelle
-
Publication number: 20030027189Abstract: The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one salicylamidyl moiety. Also provided are probes incorporating the salicylamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands of the invention.Type: ApplicationFiled: June 7, 2002Publication date: February 6, 2003Applicant: The Regents of the University of CaliforniaInventors: Kenneth N. Raymond, Stephane Petoud, Seth Cohen, Jide Xu
-
Patent number: 6503949Abstract: Disclosed is a novel class of compounds of formula (I) wherein V, A, Y, Z, R1, E, X and D are as defined in the specification. These compounds act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor, the compounds are suitable for treating or preventing glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.Type: GrantFiled: May 16, 2000Date of Patent: January 7, 2003Assignee: Noro Nordisk A/SInventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thøger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thøgersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Shenghua Shi
-
Patent number: 6492547Abstract: The present application relates to carboxylic acid amides of general formula wherein A, B and R1 to R3 are defined as in claim 1, processes for preparing them, pharmaceutical compositions containing these compounds and the use thereof and their preparation.Type: GrantFiled: December 19, 2001Date of Patent: December 10, 2002Assignee: Boehringer Ingelheim Pharma KGInventors: Henning Priepke, Norbert Hauel, Klaus Damm, Andreas Schnapp
-
Publication number: 20020173665Abstract: Compounds of formula (I) 1Type: ApplicationFiled: May 18, 2001Publication date: November 21, 2002Inventors: Chih-Hung Lee, Richard J. Perner, Daniel P. Larson, John R. Koenig, Arthur R. Gomtsyan, Guo Zhu Zheng, Stanley DiDomenico, Andrew O. Stewart, Erol K. Bayburt
-
Publication number: 20020137124Abstract: The invention relates to a process for the production of dipeptide crystals (generic formula AcXYNH2) with high purity (>95 %), by enzymatic synthesis with a protease in organic media of reversed micelles, starting from derivatives of the two constituent amino acids (AcXOEt and YNH2). A membrane and hydro-cyclone reactor was designed which enables the continuous and simultaneous synthesis and crystallisation of the dipeptides. The dipeptide crystals thus prepared are continuously removed and further separated from the remaining liquid by filtration or centrifugation. After drying, the crystals are dissolved in hot methanol. By decreasing the temperature, the dipeptide re-crystallises, originating a high purity product. After re-crystallisation the product is filtered and dried.Type: ApplicationFiled: April 26, 2002Publication date: September 26, 2002Inventors: Duarte Miguel Franca Teixeira Dos Prazeres, Ana Isabel Jorge Dias, Ana Sofia Feliciano Santos, Joaquim Manuel Sampaio Cabral, Maria Luisa Mourato Serraiheiro
-
Patent number: 6451859Abstract: Compounds having a structure according to the following formula: are effective in treating disorders such as bone disorders and glaucoma in a subject in need thereof.Type: GrantFiled: August 29, 2001Date of Patent: September 17, 2002Assignee: The Procter & Gamble CompanyInventors: Mitchell Anthony deLong, David Lindsey Soper, John August Wos, Biswanath De
-
Patent number: 6428780Abstract: Modified amino acid compounds useful in the delivery of active agents are provided. The active agents can be peptides. Methods of administration, such as oral, subcutaneous, sublingual, and intranasal administration are provided, and methods of preparation of the modified amino acid compound are provided.Type: GrantFiled: May 5, 1999Date of Patent: August 6, 2002Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Koc-Kan Ho, Donald J. Sarubbi, Sam J. Milstein, Nai Fang Wang
-
Patent number: 6420426Abstract: Disclosed are substituted phenoxyacetic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds, alone or in combination with other therapeutic agents, and methods of treatment employing the compounds and pharmaceutical compositions, as well as methods for their synthesis.Type: GrantFiled: June 23, 2000Date of Patent: July 16, 2002Assignee: The Institute for Pharmaceutical Discovery LLCInventor: Michael C. Van Zandt
-
Patent number: 6387950Abstract: Compounds which are specific or selective agonists of RAR&agr; receptors in preference over RAR&bgr; and RAR&ggr; receptors, and particularly compounds of the formula where R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt, are useful for treating a malignant disease or condition in a mammal. In treatment of solid tumors the compound exhibit synergistic anti-proliferative effect with human recombinant interferon.Type: GrantFiled: April 2, 2001Date of Patent: May 14, 2002Assignee: Allergan Sales, Inc.Inventors: Alissar Nehme, Richard L. Beard, Roshantha A. Chandraratna
-
Patent number: 6369261Abstract: Compounds having Formula 2 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.Type: GrantFiled: August 29, 2000Date of Patent: April 9, 2002Assignee: Allergan Sales, Inc.Inventors: Alan T. Johnson, Jayasree Vasudevan, Liming Wang, Roshantha A. Chandraratna
-
Patent number: 6362165Abstract: An hydroxyphenyl derivative selected from the group consisting of a compound of formula and when a compound of formula I comprises a carboxylic acid group pharmaceutically acceptable salts thereof and when a compound of formula I comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein n is 1, 2 or 3, e is 1, 2 or 3, Hal represents a halogen atom (e.g. Cl, Br, F or I), p is 0, 1 or 2, r is 0, 1 or 2, X and X′ each independently represents a single bond, a saturated straight or branched hydrocarbon group of 1 to 4 carbon atoms or a straight or branched hydrocarbon group of 2 to 4 carbon atoms comprising a carbon to carbon double bond, Ra represents H or —CH3, and Raa represents H or —CH3; W may represent an amino acid residue or fragment. These compounds may be used to inhibit the activity of HIV integrase.Type: GrantFiled: March 27, 2000Date of Patent: March 26, 2002Assignee: Pharmacor Inc.Inventors: Gilles Sauvé, Jocelyn Yelle
-
Publication number: 20020035281Abstract: The present inventintion relates to the formation of an amido ester having the formula:Type: ApplicationFiled: August 30, 2001Publication date: March 21, 2002Applicant: The Procter & Gamble CompanyInventors: Michael Eugene Burns, Michael Steven Gibson, David William York
-
Patent number: 6348593Abstract: A process for preparing folic acid, which comprises reacting a tetraalkoxypropanol of the general formula I, in which the substituents R are C1-C4-alkyl, with triaminopyrimidone of the formula II and p-aminobenzoyl-L-glutamic acid of the formula IIIType: GrantFiled: February 3, 2000Date of Patent: February 19, 2002Assignee: BASF AktiengesellschaftInventors: Jörg Botzem, Hagen Jaedicke, Michael John, Joachim Paust
-
Patent number: 6337350Abstract: Derivatives of aryl and heterocyclic ureido and aryl and heterocyclic carboxamido phenoxy isobutyric acids have been found to inhibit the nonenzymatic glycation of proteins which often results in formation of advanced glycation endproducts and crosslinks. Many other phenoxyisobutyric acid derivatives as well as certain other compounds as set out in this disclosure also have been found to inhibit the nonenzymatic glycation of proteins. The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of reducing sugars in the blood and in the intracellular environment such as occurs with diabetes. The structural and functional integrity of the affected molecules become perturbed by these modifications and can result in severe consequences.Type: GrantFiled: April 5, 2000Date of Patent: January 8, 2002Assignee: City of HopeInventors: Samuel Rahbar, Iraj Lalezari
-
Patent number: 6331570Abstract: Disclosed is the (R)-enantiomer of the formula which has unexpectedly been found to possess all of the biological activity of the racemic compound disclosed in the prior art as an RAR&ggr;-specific agonist.Type: GrantFiled: September 21, 1999Date of Patent: December 18, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Makonen Belema, Fred C. Zusi, Kenneth M. Tramposch
-
Patent number: 6329546Abstract: The caged amino acid in accordance with the present invention has the structure represented by the following formula 1: where X and Y each represent a halogen atom, an alkyl group, an alkyloxy group, an alkylamino group, or a benzo group; R1 represents a hydrogen atom or an alkyl group; R2 and R3 each represent a hydrogen atom or an alkyl group; A represents an amino acid residue; and M represents a hydrogen atom, an alkali metal, or an alkaline-earth metal.Type: GrantFiled: January 11, 2000Date of Patent: December 11, 2001Assignee: Laboratory of Molecular BiophotonicsInventor: Hirofumi Shiono
-
Publication number: 20010039293Abstract: Compounds which are specific or selective agonists of RAR&agr; receptors in preference over RAR&bgr; and RAR&ggr; receptors, and particularly compounds of the formula 1Type: ApplicationFiled: April 2, 2001Publication date: November 8, 2001Applicant: Allergan Sales, Inc.Inventors: Alissar Nehme, Richard L. Beard, Roshantha A. Chandraratna
-
Patent number: 6310245Abstract: The invention relates to 2-benzoylcyclohexane-1,3-diones of the formula I where R1, R2 are hydrogen, nitro, halogen, cyano, thiocyanato, alkyl, haloalkyl, alkoxyalkyl, alkenyl, alkynyl, —OR5, —OCOR6, —OSO2R6, —SH, —S(O)nR7, —SO2OR5, —SO2NR5R8, —NR8SO2R6 or —NR8COR6; R3 is hydrogen, alkyl, haloalkyl, alkenyl or alkynyl; R4 is hydrogen, unsubstituted or substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, —COR9, —CO2R9, —COSR9 or —CONR8R9; X is oxygen or sulfur; Z is oxygen or NR8; m is 0 or 1; n is 0, 1 or 2; R5 is hydrogen, alkyl, haloalkyl, alkoxyalkyl, alkenyl or alkynyl; R6 is alkyl or haloalkyl; R7 is alkyl, haloalkyl, alkoxyalkyl, alkenyl or alkynyl; R8 is hydrogen or alkyl; R9 is alkyl, alkenyl, alkynyl, phenyl or benzyl; R10 is alkyl, haloalkyl, alkenyl or alkynyl; Q is an unsubstituted or substituted cyclohexane-1,3-dione ring which is linked in the 2-position; where m is 1 if R3 isType: GrantFiled: June 23, 1999Date of Patent: October 30, 2001Assignee: BASF AktiengesellschaftInventors: Uwe Kardorff, Regina Luise Hill, Michael Rack, Wolfgang von Deyn, Stefan Engel, Martina Otten, Matthias Witschel, Ernst Baumann, Joachim Rheinheimer, Guido Mayer, Ulf Misslitz, Karl-Otto Westphalen, Helmut Walter
-
Patent number: 6245938Abstract: A method of separating a racemic mixture of amino acid enantiomers, which entails reacting the mixture with a 4-pentenoyl compound, thereby derivatizing the enantiomers to form two diastereomers, and separating the diastereomers.Type: GrantFiled: November 14, 1997Date of Patent: June 12, 2001Assignee: University of Virginia Patent FoundationInventors: Sidney Hecht, Michiel Lodder
-
Patent number: 6229011Abstract: Compounds of the formula: are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.Type: GrantFiled: August 21, 1998Date of Patent: May 8, 2001Assignee: Hoffman-La Roche Inc.Inventors: Li Chen, Robert William Guthrie, Tai-Nang Huang, Achyutharao Sidduri, Jefferson Wright Tilley, Kenneth Gregory Hull
-
Patent number: 6172112Abstract: The present invention provides new retinoid compounds and uses of the compounds in humans and animals for chemoprevention of skin and/or breast cancer and for therapy of leukemia.Type: GrantFiled: April 6, 1999Date of Patent: January 9, 2001Assignee: UAB Research FoundationInventors: Wayne J. Brouillette, Donald D. Muccio
-
Patent number: 6114386Abstract: A sialidase inhibitor of the shown formula I: ##STR1## where dashed lines d.sub.1 and d.sub.2, X.sub.1, R.sub.1, R.sub.2, R.sub.6, R.sub.3, R.sub.4 and R.sub.5 are as described in the specification; or an analog, pharmaceutically acceptable salt, or derivative of the inhibitor, with the proviso that the inhibitor is not HANBA GBA or Neu5Ac2en. The inhibitor in a composition with a pharmaceutically acceptable carrier. Methods of making a pharmaceutical composition of an acceptable carrier and the inhibitor. Methods of inhibiting sialidase and methods of treating and preventing bacterial or trypanosomal infection using the inhibitor.Type: GrantFiled: October 14, 1997Date of Patent: September 5, 2000Assignee: University of AlabamaInventors: Ming Luo, Clinton L. White
-
Patent number: 6090850Abstract: A class of novel naphthyl glyoxamide compounds of formula (I) is disclosed together with a process for making the novel naphthyl glyoxamide compounds and the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.Type: GrantFiled: June 9, 1998Date of Patent: July 18, 2000Assignee: Eli Lilly and CompanyInventors: Theodore Goodson, Jr., David K. Herron
-
Patent number: 6072042Abstract: The present invention provides a bis (aminocarbonylnaphthol) derivative which is useful as a raw material for novel azo pigments by bisamidation of each one carboxyl group of two 2-hydroxynaphthalene-3,6-dicarboxylic acids using an aliphatic or aromatic diamine.Type: GrantFiled: June 5, 1998Date of Patent: June 6, 2000Assignee: Kabushiki Kaisha Ueno Seiyaku Oyo KenkyujoInventors: Ryuzo Ueno, Masaya Kitayama, Kenji Minami, Hiroyuki Wakamori, Katsunori Tanikawa, Mariko Tanigawa
-
Patent number: 6051584Abstract: Novel compounds of the general formula (I) which have hemoregulatory activities and can be used to stimulate haematopolesis and for the treatment of viral, fungal and bacterial infectious diseases ##STR1##Type: GrantFiled: November 23, 1998Date of Patent: April 18, 2000Assignees: SmithKline Beecham Corporation, Nycomed Austria GmbHInventors: Pradip Kumar Bhatnagar, Michael Hartmann, Johann Hiebl, Peter Kremminger, Franz Rovenszky